Gilead gains on report claiming COVID-19 drug effectiveness

Share

The university hospital is participating in lab tests of the drug. The trial's criteria allows for the treatment of patients early in their clinical course and, in some cases, at times where they might have otherwise been intubated.

COVID-19 patients, who are being administered an experimental drug called remdesivir, have been recovering quickly, with most going home in days or a few weeks.

"The best news is that most of our patients have already been discharged, which is great".

US stocks jumped on Friday following President Donald Trump's new guidelines to reopen the economy and on a report of a drug to potentially treat COVID-19, while Boeing headed higher on plans to resume production.

Joshua Mahony, senior market analyst at share trading firm IG, said: "Trial results have breathed a new sense of optimism into markets, with many seeing this as the potential begging of the end for this coronavirus crisis". STAT has obtained video of Kathleen Mullane, the University of Chicago's infectious disease specialist who is overseeing the studies, sharing with her colleagues updates on the trials, including how almost all of the patients have been discharged in less than a week.

"We will wait for the results from the World Health Organization solidarity trial and also see if some other companies can work on this to proceed further".

Saudi Arabia-Russia oil talks delayed
The members of OPEC and their allied oil producers are scheduled to meet Thursday to discuss output cuts. Trump said last week he had made no concessions and did not agree to a US production cut.


"When we start [the] drug, we see fever curves falling", Mullane reportedly said. Gilead is set to release more fulsome clinical data later this month.

All told, 237 out of a target study population of 300 were enrolled before it was placed on hold, they said, and with no data being revealed "any benefits were likely inconclusive", they suggested. While the trial in moderate patients contains a placebo group, Gilead's trial of severe patients does not. President Donald Trump outlined plans for the reopening and investors assessed a report that Gilead Sciences Inc.is seeing improvements in coronavirus sufferers taking its drug.

Reporters write speculative article based on leaked video (was it unauthorized video conf recording?) and not only does remdesivir manufacturer Gilead $GILD stock surge 10% but the whole stock market poised to jump 3%.

In a statement, Gilead said: "What we can say at this stage is that we look forward to data from ongoing studies becoming available".

Someone needs to write a novel!

Share